Daily Medical Update

Fatty Liver Disease / MASLD (Non-pharmacologic management)

Thursday, March 26, 2026

🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.

1. Self-Directed High-Intensity Interval Versus Moderate Continuous Training on Cardiometabolic Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.

Scandinavian journal of medicine & science in sports (2026) - Randomized controlled trial

Key Findings

  • Both HIIT and moderate continuous training significantly reduced hepatic steatosis versus observation over 24 weeks, with no significant between-exercise difference for liver fat.
  • HIIT produced greater improvement in VO2peak than moderate continuous training, indicating superior cardiorespiratory conditioning despite similar steatosis effect.

📋 Practice Implication: In counseling, prioritize consistent exercise participation for liver-fat improvement, and tailor intensity to patient preference and fitness goals rather than insisting on HIIT for all.

2. Association of total and regional fat-to-muscle ratio with the risk of metabolic dysfunction-associated fatty liver disease and other chronic liver diseases.

Hepatology international (2026) - Prospective cohort study

Key Findings

  • In 356,833 UK Biobank participants, highest versus lowest fat-to-muscle ratio was associated with substantially higher incident MASLD risk (HR range 2.29-2.76).
  • Associations for advanced outcomes including cirrhosis, liver-related mortality, and HCC were strongest in men, showing sex-specific risk patterns.

📋 Practice Implication: Primary care prevention plans should pair weight reduction with muscle-preserving strategies because adverse fat-to-muscle balance carries independent liver risk.

3. Metabolic dysfunction-associated steatotic liver disease and incident coronary events with revascularization: A nationwide cohort study.

Atherosclerosis (2026) - Nationwide cohort study

Key Findings

  • In 211,881 adults, MASLD was associated with increased incidence of ACS and MI requiring revascularization after multivariable adjustment.
  • Adjusted hazard ratio estimates were generally around 1.3-1.4 across major strata, indicating increased coronary event risk.

📋 Practice Implication: Manage MASLD as a cardiovascular risk amplifier by intensifying blood pressure, lipid, glycemic, and lifestyle risk reduction alongside liver monitoring.

💡 Summary

Recent evidence supports lifestyle-first MASLD care with emphasis on sustained exercise and long-term weight control, while also reinforcing cardiovascular risk integration. Exercise adherence appears more important than intensity for liver-fat reduction, though higher-intensity training may add fitness gains. Population studies also show that cardiometabolic and body-composition risk stratification can improve early identification and prevention of fibrosis and cardiometabolic events.

Generated from 100 PubMed abstracts · RCTs and Meta‑analyses only

Next topic: Anemia of Chronic Disease & Workup

Unsubscribe · Subscribe